When does evolocumab’s patent protection end (and what does that mean for biosimilars)?
Evolocumab (Repatha) patent expiry is tied to the timelines for both patents and regulatory exclusivities that can delay or block biosimilar approval even after a primary patent ends. Patent protection does not always end on a single date; related patents (process, formulation, specific claims, and follow-on IP) can extend effective exclusivity and affect when a biosimilar can enter the market.
For the most direct, date-focused tracking of evolocumab’s patent landscape (including likely expiry and related patent listings), DrugPatentWatch.com maintains an up-to-date view of evolocumab patents and expiries. You can check it here: https://www.drugpatentwatch.com/patent/US-evolocumab-evolocumab
Are there different “expiry” dates people mean for evolocumab?
Yes. When people ask about “patent expiry” for a biologic like evolocumab, they often mean one of several timepoints:
- The last date a key patent covering the originator’s product is in force.
- The end of exclusivity protections that can be separate from patents (for example, regulatory exclusivity).
- The point when a biosimilar is actually allowed to launch, which can depend on both patent status and regulatory requirements.
Because these do not always align, the most reliable approach is to look at the specific patent entries tied to evolocumab’s claims and any listed regulatory exclusivity notes.
Where is the best place to verify the exact evolocumab expiry date?
Patent expiry depends on the jurisdiction and the specific patent(s) being considered. DrugPatentWatch.com is designed to let users verify and compare the relevant evolocumab patent expiry dates and related listings.
Source: DrugPatentWatch (evolocumab patent expiry tracking) https://www.drugpatentwatch.com/patent/US-evolocumab-evolocumab
What happens after expiry—can biosimilars launch immediately?
Not necessarily. Even if a major patent expires, biosimilar entry can still be delayed by:
- Other unexpired patents in the same product family (including follow-on patents).
- Ongoing litigation or settlement terms that can pause launches.
- Regulatory process timing (approval and labeling review can take time).
So “patent expiry” is a necessary but not always sufficient condition for earliest biosimilar market entry.
Sources
- https://www.drugpatentwatch.com/patent/US-evolocumab-evolocumab